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Abstract The cleavage site of human insulin-like growth factor
binding protein-3 by urinary prostate specific antigen was
examined. human insulin-like growth factor binding protein-3
was incubated with urinary prostate specific antigen at 37‡C and
its proteolyzed fragments were separated by a reversed phase
HPLC followed by N-terminal amino acid sequence analysis,
demonstrating that the cleavage mainly occurred at Tyr-159. The
synthetic peptide including Tyr-159 was also cleaved at the same
site, although its reaction rate was relatively low. These results
indicate that human insulin-like growth factor binding protein-3
is specifically cleaved at Tyr-159 by prostate specific antigen.
human insulin-like growth factor binding protein-3 was pre-
viously reported to be cleaved at five sites including Arg-97, Arg-
132, Tyr-159, Phe-173 and Arg-179 by another group, however,
prostate specific antigen preparation is possibly contaminated by
trypsin-like protease. In contrast, our purified urinary prostate
specific antigen had only a chymotrypsin-like activity, demon-
strating that prostate specific antigen has the high substrate
specificity for human insulin-like growth factor binding protein-
3.
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1. Introduction
Prostate speci¢c antigen (PSA) is a glycoprotein with a
molecular weight of 33 000^34 000 containing approximately
7% (w/w) carbohydrate [1,2], which was puri¢ed from human
seminal plasma [3,4] or prostatic tissues [1]. Recently, urinary
PSA (uPSA) was puri¢ed from human urine and its detailed
physicochemical properties were investigated to be almost
identical with those of PSA from seminal plasma (sPSA) [5].
While, PSA preparations have been made with di¡erences in
the enzyme speci¢city. In one case, it had both a kallikrein-
like and a chymotrypsin-like activity [6] and in others, its
activity was restricted to either of them [7^9]. However, sev-
eral PSA preparations are found to be contaminated by tryp-
sin-like protease such as hK2 [10] and recombinant PSA has
been reported to have only a chymotrypsin-like activity in-
trinsically [11^13]. Recently, we puri¢ed uPSA from human
urine, which contained both a kallikrein-like and a chymo-
trypsin-like activity [5]. In this report, uPSA was puri¢ed ex-
haustively to have only a chymotrypsin-like activity.
Furthermore, PSA was previously identi¢ed as one of the
insulin-like growth factor binding protein-3 (IGFBP-3) specif-
ic proteases [14,15]. In fact, seminal plasma was found to
contain fragments of IGFBP-3 corresponding to those gener-
ated by PSA cleavage of IGFBP-3 in vitro [14]. These ¢ndings
suggest that PSA may be an important modulator of IGF
action by regulating the a⁄nity of IGFBP-3 for IGF.
PSA is also well known as a clinical marker of prostate
cancer or benign prostatic hyperplasia (BPH) and its serum
value is useful for diagnosis of these diseases and monitoring
its clinical stage, tumor volume and histological grade [16].
There is a hypothesis that the concentration of free IGF in-
creases by IGFBP-3 degradation by PSA in prostate tissue
and ¢nally, it may contribute to abnormal prostate cell
growth [14,15,17^19]. In order to investigate the regulatory
mechanism of the IGF-IGFBP-3 system by PSA, it is very
important to clarify the cleavage speci¢city of IGFBP-3 by
PSA. In a previous report, the cleavage sites of IGFBP-3 by
sPSA were demonstrated to be Arg-97, Arg-132, Tyr-159,
Phe-173 and Arg-179 [15]. The authors say that three sites
(Arg-97, Arg-132, Arg-179) are consistent with a kallikrein-
like activity and two sites (Tyr-159, Phe-173) are consistent
with a chymotrypsin-like activity of PSA. However, trypsin-
like proteases are possibly contaminated in the PSA prepara-
tion puri¢ed from seminal plasma. In this report, the cleavage
speci¢city of IGFBP-3 was investigated by the use of uPSA
containing only a chymotrypsin-like activity and further, its
speci¢city was also con¢rmed in a peptide level.
2. Materials and methods
2.1. Puri¢cation of prostate speci¢c antigen from human urine
Human fresh urine was adsorbed to chitosan and the pass through
fraction was precipitated with ammonium sulfate (60% saturation).
The precipitate was dialyzed against 50 mM sodium phosphate bu¡er
(pH 5.5) and it was applied to a TSK-gel CM-Toyopearl 650C (TO-
SOH) column (10U15 cm) equilibrated with 50 mM sodium phos-
phate bu¡er (pH 5.5). The PSA was eluted with 0.5 M NaCl in the
bu¡er, concentrated and the bu¡er exchanged to 50 mM Tris-HCl
containing 1 M ammonium sulfate (pH 8.0). The concentrate was
applied to a TSK-gel Phenyl-Toyopearl 650S (TOSOH) column
(2.5U20 cm), equilibrated with 50 mM Tris-HCl containing 1 M
ammonium sulfate (pH 8.0) and eluted with a linear gradient of am-
monium sulfate (1 MC0 M). After concentrating the PSA fraction, it
was applied to a Sephacryl S-200 HR (Amersham Pharmacia Biotech)
column (3U80 cm), equilibrated with 50 mM Tris-HCl (pH 8.0) con-
taining 0.15 M NaCl. After the PSA fraction was collected and con-
centrated, it was applied to a Con A-Sepharose (Amersham Pharma-
cia Biotech) column (1U5 cm), equilibrated with 50 mM Tris-HCl
(pH 7.4) containing 0.5 M NaCl and eluted with 0.2 M K-methyl-D-
mannoside in the bu¡er. The eluate was concentrated and ammonium
sulfate was added to adjust its concentration to 1 M. It was applied to
an Alkyl-Superose HR5/5 (Amersham Pharmacia Biotech), equili-
brated with 50 mM Tris-HCl (pH 8.0) containing 2 M ammonium
sulfate (bu¡er A) and eluted with a linear gradient of 50 mM Tris-
HCl (pH 8.0) (bu¡er B). Separation conditions were as follows: £ow
rate: 0.5 ml/min, detection: absorbance at 280 nm, HPLC system:
Shimadzu LC-10A, gradient program: 0^10 min: 0% B, 10^20 min:
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0^40% B, 20^35 min: 40% B, 35^45 min: 40^50% B, 45^55 min: 50^
100% B. The PSA fraction was applied to a Cosmosil 5C18-AR-300
(0.45U15 cm, Nacalai Tesque) using 0.1% tri£uoroacetic acid (TFA)-
acetonitrile (AN) system. Conditions were as follows: £ow rate: 1 ml/
min, detection: absorbance at 280 nm, HPLC system: Shimadzu LC-
10A, gradient program: 0^15 min: 0^32% AN, 15^25 min: 32% AN,
25^35 min: 32^40% AN, 35^40 min: 40^80% AN.
The PSA content was determined using MARKIT-M PA (Dai-nip-
pon Pharmaceutical), an ELISA kit for PSA measurement. The total
protein was determined by the method of Lowry et. al [20].
2.2. Measurement of the enzyme activity
For measurement of the enzyme activity, MeO-Suc-Arg-Pro-Tyr-
pNA (S-2586) (Chromogenix) and Pro-Phe-Arg-pNA (S-2302) (Chro-
mogenix) were used as chromogenic substrates. The substrates and
PSA were diluted with 0.1 M Tris-HCl (pH 8.0) containing 0.05%
Tween-20 (bu¡er C), which prevents the adsorption of PSA and
does not inhibit the enzymatic activity of PSA. After 10 Wl of the
synthetic substrate solution (1 mM) and 32 Wl of bu¡er C were pre-
incubated at 37‡C for 5 min, 8 Wl of PSA solution (85 Wg/ml) was
added. The reaction mixture was incubated at 37‡C for 60 min, fol-
lowed by adding 100 Wl of 0.6 M AcOH to stop the reaction. Absorp-
tion of free p-nitroaniline at 382 nm was measured with a UV spec-
trometer DU640 (Beckman).
2.3. Electrophoresis and Western immunoblotting
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was carried
out as described by Laemmli [21] with a 10^20% gradient gel, Maltigel
10/20 (Daiichi Pure Chemicals). For Western immunoblotting, the gel
was electroblotted to a polyvinylidene di£uoride (PVDF) membrane.
The membrane was incubated with rabbit anti-IGFBP-3 serum (Up-
state Biotechnology) and ,after washing, with HRP-conjugated anti-
rabbit IgG (Promega) followed by developing with Renaissance West-
ern Blot Chemiluminescence Reagent (NEN Life Science Products).
2.4. Degradation of recombinant human IGFBP-3 by uPSA
Recombinant human IGFBP-3 (20 Wg, Upstate Biotechnology) ex-
pressed in Chinese hamster ovary (CHO) cells was dissolved in 200 Wl
of 0.1 M Tris-HCl containing 0.05% Tween-20 and added to 2 Wg of
uPSA followed by an incubation at 37‡C for 24 h. A small portion of
reaction mixture was analyzed by Western immunoblotting and others
were applied to a Cosmosil 5C18-MS (0.45U15 cm, Nacalai Tesque)
using a 0.1% TFA-AN system, followed by the separation of degra-
dation products. The conditions were as follows: £ow rate: 1 ml/min,
detection: absorbance at 220 nm, system: Gilson HPLC system, gra-
dient program: 0^60 min: 0^40% AN. Each peak was collected and
its N-terminal amino acid sequence was determined by a Protein
Sequencer 476A (PE Applied Biosystems).
2.5. Degradation of recombinant human IGFBP-3 by sPSA
sPSA was purchased from Calbiochem, but the sPSA also degraded
S-2302 slightly, so it was puri¢ed by reversed phase (RP)-HPLC as
described in the ¢nal step of uPSA puri¢cation before it was used for
the degradation of IGFBP-3. The degradation was performed by the
method as shown in Section 2.3.
2.6. Peptide synthesis
Peptides described below were synthesized by use of a Peptide Syn-
thesizer 432A (PE Applied Biosystems) and puri¢ed by RP-HPLC.
Peptides: SP1 DSQRYKVDYE, SP2 DSQRYKVD, SP3 QRYKV-
DYE and SP4 QRYKVD
2.7. Degradation of synthetic peptide by uPSA
Synthetic peptide (50 nmol) and uPSA (8.7 Wg, 0.26 nmol) were
incubated at 37‡C in 0.1 M Tris-HCl (pH 8.0) bu¡er containing
0.05% Tween-20. After 24 h, the reaction mixtures were applied to
a Cosmosil 5C18-AR-II (0.45U15 cm, Nacalai Tesque) using the 0.1%
TFA-AN system and the degraded peptides were obtained. Condi-
tions were as follows: £ow rate: 1 ml/min, detection: absorbance at
220 nm, HPLC system: Shimadzu LC-10A, gradient program: 0^24
min: 0^24% AN, 24^30 min: 24^100% AN, 30^35 min: 100% AN.
The cleavage site was determined by amino acid composition analysis
of degraded peptides.
3. Results and discussion
3.1. Puri¢cation of uPSA
Previously, we reported the puri¢cation and characteriza-
tion of PSA from human urine [5]. In the report, we demon-
strated that the physicochemical properties of puri¢ed uPSA
were almost identical with those of sPSA and it had both
trypsin-like and chymotrypsin-like activities. However, re-
cently, some of the sPSAs were found to be contaminated
by hK2, which is a member of the kallikrein family and has
a trypsin-like activity [22], and PSA has been reported to have
a chymotrypsin-like activity but not a trypsin-like activity [9^
11]. These results suggest that our puri¢ed PSA is also con-
taminated by trypsin-like proteases such as hK2. Then, we re-
puri¢ed uPSA by the improved method.
The puri¢cation was achieved by six steps of column chro-
matography (Table 1). At the step of Alkyl-Superose HR5/5,
almost all of the inactive PSAs, which had some internal
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Table 1
Puri¢cation of PSA from human urine
Puri¢cation step PSA assayed by ELISA Total protein Speci¢c activity Recovery
a (mg) b (mg) (a)/(b) (%)
Ammonium sulfate precipitation 13.0 33986 3.84U1034 100.0
CM-Toyopearl 650C 8.31 1404 5.92U1033 63.8
Phenyl-Toyopearl 650S 4.83 266 0.0182 37.1
Sephacryl S-200 HR 3.92 74.3 0.0528 30.1
ConA-Sepharose 2.74 23.3 0.118 21.0
Alkyl-Superose HR5/5 0.78 5.0 0.158 6.0
Cosmosil 5C18-AR-300 0.49 3.3 0.146 3.7
Fig. 1. The proteolysis of IGFBP-3 by uPSA analyzed by Western
immunoblotting. (a) After the incubation of IGFBP-3 with uPSA at
37‡C for 5 h (lane 1), 8 h (lane 2) and 24 h (lane 3). (b) After the
separation by RP-HPLC. The lanes 1^5 correspond to each peak
number 1, 2, 3, 4 and 6, respectively.
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cleavages [9] and migrated at a lower position than intact PSA
on SDS-PAGE under the reduced condition, could be re-
moved e⁄ciently (data not shown). Some other protease ac-
tivities were detected by enzyme assays using a chromogenic
substrate after this step (data not shown). In order to remove
other proteases, RP-HPLC was used as a ¢nal step. This
procedure was successful for the puri¢cation of hK2 [22] be-
cause of its unusual resistance to the severe conditions in the
presence of acetonitrile and 0.1% TFA. In the similar condi-
tion, uPSA was also stable and other contaminated proteases
could be removed. As shown in Table 2, puri¢ed uPSA
cleaved S-2586 but not S-2302, indicating that it has an
only chymotrypsin-like activity.
As shown in Table 1, the PSA content in the ¢nal product
measured by ELISA was low as compared with that by the
Lowry method. The ELISA kits for PSA measurement are
produced by many companies and the measured values are
di¡erent [23]. In this case, the values measured by ELISA
are estimated to be lower than the actual values.
3.2. Determination of the cleavage sites of IGFBP-3
IGFBP-3 was incubated with uPSA at 37‡C and analyzed
by Western immunoblotting after 5 h, 8 h and 24 h (Fig. 1a).
Proteolyzed fragments increase in a time-dependent manner
although its degradation rate was relatively low. The proteo-
lyzed fragments were separated by RP-HPLC as shown in
Fig. 2, followed by Western immunoblotting analysis (Fig.
1b). The amino acid sequence and the quantity of each frag-
ment were determined as shown in Table 3. Peak number 1
and 2 contained the peptides which started from Arg-132 and
Ala-98, respectively, but their amounts were small. Therefore,
they could not be detected by Western immunoblotting (Fig.
1b). Peak number 3 and 4, the major degradation products,
contained the peptides which started from Lys-160. It is con-
ceivable that the di¡erence in molecular weight of number 3
and 4 is due to the di¡erence in sugar chain [24]. In peak
number 6, none of the sequences except for N-terminal was
detected by amino acid sequence analysis although Fig. 1b
indicates that peak number 6 contained intact IGFBP-3 and
a proteolyzed fragment. This result suggests that the fragment
contained the residual portion after the release of the C-ter-
minal fragment. From the above, it is suggested that uPSA
cleaves IGFBP-3 carboxy-terminal of Tyr-159. Although a
small amount was cleaved at Arg-97 and His-131, the rates
of these cleavages are estimated to be 4.0% and 8.9% of total
cleavages (39.2 pmol), respectively. Therefore, it is possibly
considered that these cleavages at Arg-97 and His-131 are
due to very small amounts of contaminated proteases which
were not detected by the chromogenic substrate assay.
We also examined sPSA. The purchased sPSA was puri¢ed
by RP-HPLC before use, because it had a slight trypsin-like
activity (Table 2). The cleavage sites and proteolysis rate of
sPSA were almost identical to those of uPSA (data not
shown).
Previously, Fielder et. al. reported that the cleavage sites of
IGFBP-3 (Fig. 3) by sPSA were Arg-97, Arg-132, Tyr-159,
Phe-173 and Arg-179 [19]. They say that three sites (Arg-97,
Arg-132, Arg-179) are consistent with a kallikrein-like activity
and two sites (Tyr-159, Phe-173) are consistent with a chymo-
trypsin-like activity, but trypsin-like proteases are possibly
contained in the sPSA preparation. The cleavage at Tyr-159
was identi¢ed by our experiment. It is considered that the
cleavages at three Arg sites were due to contaminated tryp-
sin-like proteases. The cleavage at Phe-173 was not detected in
our experiment, however, this di¡erence may mainly depend
on the purity of PSA used in the experiment. It is possible that
other proteases were contaminated in the sPSA preparation.
As a minor possibility, the di¡erence in IGFBP-3 is consid-
ered. We used glycosylated rIGFBP-3, expressed in CHO
cells. On the other hand, they used a non-glycosylated one,
expressed in Escherichia coli. The presence of sugar chains
may in£uence the reactivity of PSA but a glycosylated
IGFBP-3 is more preferable in consideration of the physio-
logical condition.
3.3. Degradation of synthetic peptides
In order to con¢rm the cleavage speci¢city of uPSA, four
peptides which contain the main cleavage site Tyr-159 were
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Fig. 2. The elution pro¢le of proteolyzed IGFBP-3 by uPSA. After
the incubation of IGFBP-3 with uPSA for 24 h at 37‡C, the reac-
tion mixture was separated by RP-HPLC.
Table 3
N-terminal amino acid sequence and the quantity of the peptide
corresponding to each peak
Peak number N-terminal amino acid sequence Quantity (pmol)
1 R(132)VSPD 3.1
2 A(98)YLLP 7.0
3 K(160)VDYE 42.1
A(98)YLLP Trace
4 K(160)VDYE 9.1
5 G(1)ASSG 53.2
K(160)VDYE 17.1
6 G(1)ASSG 163.3
The quantity was determined by N-terminal amino acid sequence
analysis.
Table 2
Enzymatic activity of uPSA and sPSA
Substrate uPSA sPSA
Pro-Phe-Arg-pNA (S-2302) N.D. 4.9
MeO-Suc-Arg-Pro-Tyr-pNA (S-2586) 20.5 17.9
Unit: pNA nmol/min/mg protein.
Fig. 3. The cleavage sites of IGFBP-3 by uPSA (with an arrow).
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synthesized (Table 4). Each peptide was incubated with uPSA
at 37‡C and after 24 h, the reaction mixtures were analyzed by
RP-HPLC. Table 4 also shows the rates of peptides degraded
by uPSA, which were calculated based on peak areas of de-
graded peptides. SP1 was the most speci¢c for uPSA and SP3
and SP4 were hardly cleaved. In SP1, a Tyr residue corre-
sponding to the position 163 was not cleaved. This result
suggests that uPSA has a high speci¢city for the sequence
around Tyr-159, although its degradation rate is relatively
low. The results of SP2VSP4 indicated that the two residues,
Asp-Ser, are particularly important to the speci¢city of uPSA.
In this paper, the major cleavage site of IGFBP-3 by PSA
was determined to be Tyr-159 and its substrate speci¢city was
also con¢rmed by use of synthetic peptides. These results
demonstrated that PSA had a high substrate speci¢city for
IGFBP-3.
Recently, PSA has been considered to be one of the
IGFBP-3 speci¢c proteases and its involvement for the IGF-
IGFBP-3 system has been supposed [14,15,17^19]. The PSA
concentration in serum or prostate tissue increases in patients
with prostate cancer or BPH. Therefore, there is a hypothesis
that the concentration of free IGF increases by IGFBP-3 deg-
radation by PSA in prostate tissue, resulting in abnormal
prostate cell growth, which suggests that the block of proteol-
ysis of IGFBP-3 by PSA may contribute to the improvement
of prostatic disease such as prostate cancer or BPH. In this
point, the amino acid sequence around Tyr-159, which we
determined, may be utilized for the design of a speci¢c inhib-
itor for PSA.
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Table 4
The degradation rate of synthetic peptides by uPSA
Peptide Sequence Degradation rate (nmol/h)
SP1 DSQRYKVDYE 0.62
SP2 DSQRYKVD 0.17
SP3 QRYKVDYE 0.012
SP4 QRYKVD Trace
Degradation rates are calculated from peak areas of peptides: D/
(D+S)U50 (nmol)/24 (h). D, total area of degraded products; S,
area of remained intact peptide.
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